Document is current
Any future updates will be listed below
-
Authors
Martín-Martín, Lourdes https://orcid.org/0000-0001-7996-570X
Gutiérrez-Herrero, Sara https://orcid.org/0000-0001-5507-3985
Herrero-García, María https://orcid.org/0000-0001-8719-7165
Martín García-Sancho, Alejandro https://orcid.org/0000-0001-6330-1028
Yeguas, Ana
Martín-López, Ana-África
López-Corral, Lucía https://orcid.org/0000-0003-1908-5596
Pérez-López, Estefanía
García-Blázquez, Marta
Sánchez-Guijo, Fermín https://orcid.org/0000-0002-7076-7739
Vidriales, María Belén https://orcid.org/0000-0001-5049-3673
Gaipa, Giuseppe
,
Orfao, Alberto
,
Vidriales, María Belén
Orfao, Alberto https://orcid.org/0000-0002-0007-7230
-
Funding
Funding for this research was provided by:
Accelerator Award-Cancer Research UK/AIRC/AECC-INCAR (GEACC18001ORF).
- License Information
-
More Information
Article History
Received: 26 February 2024
Revised: 26 April 2024
Accepted: 30 April 2024
First Online: 17 May 2024
Competing interests
: AMG-S reports honoraria from Roche, BMS, Janssen, Gilead/Kite, Takeda, Eusa Pharma, Sobi, Ideogen, Incyte, Kyowa Kirin and BeiGene; consulting fees from Roche, BMS, Kyowa Kirin, Novartis, Gilead/Kite, Incyte, Lilly, Miltenyi, Ideogen, Abbvie, Sobi, Genmab, GSK, Regeneron and AstraZeneca; travel and accommodation support from Gilead/Kite, Janssen, Roche and BMS. MGB reports travel and accommodation support from Gilead/Kite, LL-C reports speaker’s bureau participation for Gilead/Kite, MSD and Novartis; travel and accommodation support from Gilead/Kite, MSD and Novartis; consulting or advisory role for Novartis and Gilead/Kite; FSG reports research support from Novartis and Gilead/Kite and honoraria from Novartis, Gilead/Kite, Pfizer, BMS and Pierre-Fabré.
